[go: up one dir, main page]

NO20030304L - Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering - Google Patents

Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering

Info

Publication number
NO20030304L
NO20030304L NO20030304A NO20030304A NO20030304L NO 20030304 L NO20030304 L NO 20030304L NO 20030304 A NO20030304 A NO 20030304A NO 20030304 A NO20030304 A NO 20030304A NO 20030304 L NO20030304 L NO 20030304L
Authority
NO
Norway
Prior art keywords
antagonist
pharmaceutical formulation
new combination
serotonin agonist
serotonin
Prior art date
Application number
NO20030304A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030304D0 (no
Inventor
Sukhwinder Jossan
Bjoern M Nilsson
Kjell S Sakariassen
Jan Svartengren
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20030304D0 publication Critical patent/NO20030304D0/no
Publication of NO20030304L publication Critical patent/NO20030304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NO20030304A 2000-07-21 2003-01-20 Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering NO20030304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (fr) 2000-07-21 2001-07-19 Nouvelle association d'un agoniste de serotonine (5ht2) et d'un antagoniste de serotonine (5ht6) se presentant sous forme de formule pharmaceutique

Publications (2)

Publication Number Publication Date
NO20030304D0 NO20030304D0 (no) 2003-01-20
NO20030304L true NO20030304L (no) 2003-03-12

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030304A NO20030304L (no) 2000-07-21 2003-01-20 Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering

Country Status (18)

Country Link
EP (1) EP1301476A1 (fr)
JP (1) JP2004504376A (fr)
KR (1) KR100845450B1 (fr)
CN (1) CN1221254C (fr)
AU (2) AU8273401A (fr)
BR (1) BR0112661A (fr)
CA (1) CA2411192A1 (fr)
EA (1) EA006604B1 (fr)
HU (1) HUP0301346A3 (fr)
IL (1) IL154057A0 (fr)
MX (1) MXPA03000548A (fr)
NO (1) NO20030304L (fr)
NZ (1) NZ523216A (fr)
PL (1) PL360309A1 (fr)
SE (1) SE0002754D0 (fr)
WO (1) WO2002008178A1 (fr)
YU (1) YU2603A (fr)
ZA (1) ZA200210234B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL213134B1 (pl) * 2000-11-02 2013-01-31 Wyeth Corp 1-arylo- lub 1-alkilosulfonylo- heterocyklilobenzazole, ich zastosowanie oraz kompozycja farmaceutyczna zawierajaca te zwiazki
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
CA2450245A1 (fr) 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Derives de 4-piperazinylindole a affinite avec les recepteurs 5-ht6
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
AR039127A1 (es) * 2002-03-27 2005-02-09 Glaxo Group Ltd Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
MXPA06000795A (es) 2003-07-22 2006-08-23 Arena Pharm Inc Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo.
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
EP2018863B9 (fr) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné et utilisation
WO2007149728A2 (fr) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Dérivés d'aryl et d'hétéroaryl tétrahydrobenzazépine et leur utilisation pour traiter le glaucome
EP2020230B1 (fr) * 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combinaison d'au moins deux ligands 5-HT6
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
EP2508177A1 (fr) 2007-12-12 2012-10-10 Glaxo Group Limited Associations contenant de la 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (fr) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Procédés utiles pour la préparation de 1-[3-(4-bromo-2-méthyl-2h-pyrazol-3-yl)-4-méthoxy-phényl]-3-(2,4-difluoro‑phényl)-urée, et formes cristallines associées
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
UY32707A (es) 2009-06-15 2011-01-31 Takeda Pharmaceutical Derivados de pirazinooxazepina
WO2011071136A1 (fr) 2009-12-11 2011-06-16 アステラス製薬株式会社 Agent thérapeutique pour la fibromyalgie
MX388281B (es) 2015-06-12 2025-03-11 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamiento de un trastorno conductual del sueño rem.
HK1247555A1 (zh) 2015-07-15 2018-09-28 Axovant Sciences Gmbh 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
WO2019131902A1 (fr) 2017-12-27 2019-07-04 武田薬品工業株式会社 Agent thérapeutique pour incontinence urinaire de stress et incontinence fécale
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
HK1057536A1 (en) 2004-04-08
CN1443162A (zh) 2003-09-17
NZ523216A (en) 2005-05-27
EA006604B1 (ru) 2006-02-24
ZA200210234B (en) 2004-03-18
KR100845450B1 (ko) 2008-07-10
HUP0301346A2 (hu) 2003-08-28
YU2603A (sh) 2006-05-25
BR0112661A (pt) 2003-06-24
JP2004504376A (ja) 2004-02-12
CN1221254C (zh) 2005-10-05
PL360309A1 (en) 2004-09-06
WO2002008178A1 (fr) 2002-01-31
NO20030304D0 (no) 2003-01-20
SE0002754D0 (sv) 2000-07-21
HUP0301346A3 (en) 2005-05-30
AU8273401A (en) 2002-02-05
CA2411192A1 (fr) 2002-01-31
AU2001282734B2 (en) 2006-10-12
MXPA03000548A (es) 2004-04-05
IL154057A0 (en) 2003-07-31
EP1301476A1 (fr) 2003-04-16
EA200300183A1 (ru) 2003-08-28
KR20030036599A (ko) 2003-05-09

Similar Documents

Publication Publication Date Title
NO20030304D0 (no) Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasöytisk formulering
NO20032797D0 (no) Substituerte pyridoindoler som serotonin agonister og antagonister
DK1454901T3 (da) Farmaceutiske sammensætninger omfattende tachykininantagonister og en serotoningenoptagelseshæmmer
NO20025450L (no) Ny farmasöytisk sammensetning
PT1572707E (pt) Novos derivados fluoroglicosideos aromaticos, farmacos contendo estes compostos e sua utilizacao
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
DE60138706D1 (de) Missbrauchssichere orale opioid-agonist zubereitungen
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20003196L (no) Umiddelbart opplösende doseringsformulering
DE60212044D1 (de) Test der bukkalen Auflösung pharmazeutisch aktiver Stoffe
FI991485A0 (fi) Uusi farmaseuttinen koostumus
DK1263721T3 (da) Farmaceutiske sammensætninger, der indeholder 3-aminoazetidinderivater, nye derivater og fremstilling deraf
ITTO20010008A0 (it) Formulazione farmaceutica
NO20033384D0 (no) Farmasöytisk formulering
IS6811A (is) Lyfjafræðilegar samsetningar NMDA viðtakagerandefna
NO20032517L (no) Farmasöytisk preparat inneholdende amlodipinmaleat
NO20011503L (no) Indeno-, nafto- og benzocyklohepta-dihydrotiazolderivater, deres fremstilling og anvendelse som anorektiske legemidler
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
NO20041607L (no) Doseringsregime og farmasoytisk preparat for nodprevensjon
NO20032142D0 (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
NO20035627D0 (no) Farmasöytisk formulering
DK1230230T3 (da) Derivater af indeno-dihydrothiazol, fremstilling deraf og anvendelse som anorektiske lægemidler
NO20015149D0 (no) Nytt farmasöytisk preparat
NO20043124L (no) Aminoindanderivater som serotonin -og norepinefrin-opptaksinhibitorer
NO20035328D0 (no) Nye forbindelser og preparater som katepsinhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application